Tradestie Institutional Equity Comparison Engine

NTLA vs RCUS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NTLA Overall Edge

NTLA Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Intellia Therapeutics, Inc (NTLA) driven by superior Growth & Margin, Momentum & Technical while RCUS counters with relative strength in Options & Structure. Fundamentally, NTLA trades at N/M Forward P/E with -826.0% operating margin (-48.0% YoY revenue) versus RCUS at N/M Forward P/E and -475.0% operating margin (-65.4% YoY). In options structure, NTLA sits in BREAKDOWN (78th %ile IV; Dealer Gamma Walls on Pro) against RCUS sits in BREAKDOWN (1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
NTLA N/M vs RCUS N/M Fwd P/E
Growth & Margin Winner NTLA
Op Margin -826.0% vs -475.0% ยท YoY -48.0% vs -65.4%
Momentum & Technical Winner NTLA
1Y +15.3% vs -14.2% ยท 52W Pos 20% vs 1%
Options & Structure Winner RCUS
BREAKDOWN (78th %ile IV) vs BREAKDOWN (1st %ile IV)
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
1M Return -12.43%
1Y Return +15.34%
Forward P/E N/M
Unified AI Score
49.9 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
RCUS NYSE
Arcus Biosciences, Inc.
Pharmaceutical Preparations
$16.97
-2.64% 1D
Market Cap $2.6B
1M Return -23.28%
1Y Return -14.25%
Forward P/E N/M
Unified AI Score
48.7 / 100 HOLD
Tech 49.0 Fund 59.0 Flow 68.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NTLA +15.34% RCUS -14.25% Spread: +29.59 pp (NTLA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period NTLA Revenue RCUS Revenue NTLA Op. Margin RCUS Op. Margin Margin Edge
FY2018 $30M $10M -298.6% -656.8% NTLA
FY2019 $40M $10M -246.8% -591.4% NTLA
FY2020 $60M $80M -235.5% -159.0% RCUS
FY2021 $30M $380M -810.4% 14.1% RCUS
FY2022 $50M $40M -879.0% -736.8% RCUS
FY2023 $40M $40M -1420.5% -918.9% RCUS
FY2024 $60M $50M -923.1% -647.1% RCUS
FY2025 $70M $30M -651.7% -1169.7% NTLA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NTLA (5) vs RCUS (2)
Institutional Metric NTLA RCUS Criterion Row Winner
Market Capitalization Scale $1.5B $2.6B Larger Scale RCUS
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -48.0% -65.4% Higher Growth NTLA
Operating Margin (TTM) Profitability -826.0% -475.0% Higher Margin RCUS
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -62.6% -114.1% Higher ROE NTLA
52-Week Range Position Momentum 20% ($8โ€“$18) 1% ($17โ€“$32) Stronger Trend NTLA
Beta / 30D Volatility Risk Regime 2.30ฮฒ ยท 87% Vol 1.56ฮฒ ยท 90% Vol Lower Realized Risk NTLA
Unified Institutional Score Composite Signal 49.9 / 100 (HOLD) 48.7 / 100 (HOLD) Higher Composite NTLA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NTLA vs RCUS Buy Guide
NTLA BREAKDOWN
94d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 78th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live NTLA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
RCUS BREAKDOWN
58d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 1st %ile
IV Regime Compressed (<25th %ile)
Live RCUS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NTLA nor RCUS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.